Cabaletta Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M |
| Operating expenses | $172.2M | $125.1M | $74.7M | $54.1M | $46.3M |
| Cash from operations | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M |
| Capital expenditure | $1.2M | $2.2M | $687,000 | $2.5M | $1.2M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M |
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | $8.4M |
Shares outstanding 163.1M · Free float 99.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.